食管癌术后患者应用中药干预对生活质量及生存时间的影响研究

Effect of herbal medicine on the life quality and survival time of the esophageal cancer patients after surgery

目的 观察中药干预对术后食管癌患者的生活质量及生存时间的影响。方法 选取180例经手术治疗的食管癌患者并依据知情同意的原则分为3个治疗组,分别是单纯化疗组、单纯中药组及中药＋化疗组,每组各60例。采用生活质量核心问卷（QLQ-C30）和生存分析评估患者的生存质量和生存时间。结果 中药组、中药＋化疗组和化疗组患者的临床症状及身体功能经干预均有一定改善,但总体而言,化疗＋中药组的改善效果最佳,与另2组比较差异有统计学意义（P〈0.05）;化疗＋中药组及单纯中药组患者经干预后,机体的免疫水平改善,而化疗组患者的免疫状况下降;化疗组患者的生存时间为（27.21±3.55）个月,中药组患者的生存时间为（28.56±4.19）个月,化疗＋中药组患者的生存时间为（34.58±3.24）个月;经Log-Rank检验,3组差异有统计学意义（χ^2=5.698,P=0.037）。结论 食管癌患者术后服用中药,其生活质量、免疫状况、生存时间均明显改善,可在临床推广中药＋化疗的综合干预方案。

Objective To observe the effect of herbal medicine on the life quality and survival time of the esophageal cancer patients after surgery. Methods With their knowledge and consent, 180 esophageal cancer patients after surgery were divided into 3 groups ： the pure chemotherapy group, the pure traditional herbal medicine group and the chemotherapy ＋ herbal medicine group, each consisting of 60 patients. The quality of life questionnaire （QLQ-C30） and survival analysis were used to assess the quality of life and survival time of the patients. Results The clinical symptoms and physical functions in all the patients of the 3 groups were improved to some extent after treatment. However, on the whole, symptom improvement of the chemotherapy ＋ herbal medicine group was the most sufficient（P 〈0.05）. After intervention, the immune function of both the chemotherapy ＋ herbal medicine group and the pure herbal medicine group was improved, while that of the chemotherapy group was decreased. The survival time of the chemotherapy group was （27. 21 ±3. 55） months, while that of the herbal medicine group was （28. 56 ±4. 19） months, and that of the chemotherapy ＋ herbal medicine group was （34. 58 ±3. 24） months. By Log-rank test, statistical significance could be noted in survival time of the 3 groups （χ^2=5. 698 , P = 0. 037） . Conclusion Taking traditional herbal medicine after surgery could significantly improve the life quality, immune function and survival rate of the esophageal cancer patients, and this comprehensive intervention profile could be extended in the clinical practice.